Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

1.

Structural basis of nSH2 regulation and lipid binding in PI3Kα.

Miller MS, Schmidt-Kittler O, Bolduc DM, Brower ET, Chaves-Moreira D, Allaire M, Kinzler KW, Jennings IG, Thompson PE, Cole PA, Amzel LM, Vogelstein B, Gabelli SB.

Oncotarget. 2014 Jul 30;5(14):5198-208.

2.

Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria.

Deris ZZ, Swarbrick JD, Roberts KD, Azad MA, Akter J, Horne AS, Nation RL, Rogers KL, Thompson PE, Velkov T, Li J.

Bioconjug Chem. 2014 Apr 16;25(4):750-60. doi: 10.1021/bc500094d. Epub 2014 Mar 27.

3.

Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.

Velkov T, Roberts KD, Nation RL, Wang J, Thompson PE, Li J.

ACS Chem Biol. 2014 May 16;9(5):1172-7. doi: 10.1021/cb500080r. Epub 2014 Mar 17.

4.

A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity.

Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T.

J Antibiot (Tokyo). 2014 Feb;67(2):147-51. doi: 10.1038/ja.2013.111. Epub 2013 Oct 30.

5.

Polymyxins and analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro.

McCoy LS, Roberts KD, Nation RL, Thompson PE, Velkov T, Li J, Tor Y.

Chembiochem. 2013 Nov 4;14(16):2083-6. doi: 10.1002/cbic.201300496. Epub 2013 Sep 18.

6.

L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ

Pinson JA, Zheng Z, Miller MS, Chalmers DK, Jennings IG, Thompson PE.

ACS Med Chem Lett. 2013 Feb 14;4(2):206-210.

7.

Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J.

J Antimicrob Chemother. 2013 Oct;68(10):2311-7. doi: 10.1093/jac/dkt207. Epub 2013 Jun 7.

8.

Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.

Velkov T, Roberts KD, Nation RL, Thompson PE, Li J.

Future Microbiol. 2013 Jun;8(6):711-24. doi: 10.2217/fmb.13.39. Review.

9.

Molecular determinants of the substrate specificity of the complement-initiating protease, C1r.

Wijeyewickrema LC, Yongqing T, Tran TP, Thompson PE, Viljoen JE, Coetzer TH, Duncan RC, Kass I, Buckle AM, Pike RN.

J Biol Chem. 2013 May 31;288(22):15571-80. doi: 10.1074/jbc.M113.451757. Epub 2013 Apr 15.

10.

Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.

Nguyen W, Howard BL, Jenkins DP, Wulff H, Thompson PE, Manallack DT.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7106-9. doi: 10.1016/j.bmcl.2012.09.080. Epub 2012 Sep 29.

11.

Molecular basis for the increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid A.

Velkov T, Soon RL, Chong PL, Huang JX, Cooper MA, Azad MA, Baker MA, Thompson PE, Roberts K, Nation RL, Clements A, Strugnell RA, Li J.

Innate Immun. 2013 Jun;19(3):265-77. doi: 10.1177/1753425912459092. Epub 2012 Sep 24.

12.

Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein.

Azad MA, Huang JX, Cooper MA, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T.

Biochem Pharmacol. 2012 Aug 1;84(3):278-91. doi: 10.1016/j.bcp.2012.05.004. Epub 2012 May 12.

13.

Definition of the binding mode of a new class of phosphoinositide 3-kinase α-selective inhibitors using in vitro mutagenesis of non-conserved amino acids and kinetic analysis.

Zheng Z, Amran SI, Zhu J, Schmidt-Kittler O, Kinzler KW, Vogelstein B, Shepherd PR, Thompson PE, Jennings IG.

Biochem J. 2012 Jun 15;444(3):529-35. doi: 10.1042/BJ20120499.

14.

Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 Kinase.

Pinson JA, Schmidt-Kittler O, Frazzetto M, Zheng Z, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE.

Aust J Chem. 2012 Jan 10;65(10):1396-1404.

15.

The phytosulfokine (PSK) receptor is capable of guanylate cyclase activity and enabling cyclic GMP-dependent signaling in plants.

Kwezi L, Ruzvidzo O, Wheeler JI, Govender K, Iacuone S, Thompson PE, Gehring C, Irving HR.

J Biol Chem. 2011 Jun 24;286(25):22580-8. doi: 10.1074/jbc.M110.168823. Epub 2011 Apr 19.

16.

Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers.

Albiston AL, Diwakarla S, Fernando RN, Mountford SJ, Yeatman HR, Morgan B, Pham V, Holien JK, Parker MW, Thompson PE, Chai SY.

Br J Pharmacol. 2011 Sep;164(1):37-47. doi: 10.1111/j.1476-5381.2011.01402.x. Review.

17.

Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.

Pinson JA, Schmidt-Kittler O, Zhu J, Jennings IG, Kinzler KW, Vogelstein B, Chalmers DK, Thompson PE.

ChemMedChem. 2011 Mar 7;6(3):514-22. doi: 10.1002/cmdc.201000467. Epub 2011 Jan 4.

18.

Design, synthesis, and evaluation of a new fluorescent probe for measuring polymyxin-lipopolysaccharide binding interactions.

Soon RL, Velkov T, Chiu F, Thompson PE, Kancharla R, Roberts K, Larson I, Nation RL, Li J.

Anal Biochem. 2011 Feb 15;409(2):273-83. doi: 10.1016/j.ab.2010.10.033. Epub 2010 Nov 2.

19.

Use of Kv1.3 blockers for inflammatory skin conditions.

Nguyen W, Howard BL, Neale DS, Thompson PE, White PJ, Wulff H, Manallack DT.

Curr Med Chem. 2010;17(26):2882-96. Review.

20.

Structure--activity relationships of polymyxin antibiotics.

Velkov T, Thompson PE, Nation RL, Li J.

J Med Chem. 2010 Mar 11;53(5):1898-916. doi: 10.1021/jm900999h. Review. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk